Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Cash & Equivalents (2016 - 2026)

Anaptysbio filings provide 11 years of Cash & Equivalents readings, the most recent being $248.5 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 151.9% to $248.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $248.5 million, a 151.9% increase, with the full-year FY2025 number at $238.2 million, up 93.53% from a year prior.
  • Cash & Equivalents hit $248.5 million in Q1 2026 for Anaptysbio, up from $238.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $248.5 million in Q1 2026 to a low of $26.3 million in Q3 2023.
  • Median Cash & Equivalents over the past 5 years was $71.8 million (2024), compared with a mean of $102.3 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 85.62% in 2022 and later soared 628.58% in 2024.
  • Anaptysbio's Cash & Equivalents stood at $71.3 million in 2022, then tumbled by 49.56% to $36.0 million in 2023, then soared by 242.22% to $123.1 million in 2024, then soared by 93.53% to $238.2 million in 2025, then increased by 4.31% to $248.5 million in 2026.
  • The last three reported values for Cash & Equivalents were $248.5 million (Q1 2026), $238.2 million (Q4 2025), and $109.8 million (Q3 2025) per Business Quant data.